Lege Artis Medicinae

[Clinical trials for evaluating cardiovascular safety of SGLT-2- inhibitor drugs in patients with type 2 diabetes]

JERMENDY György

MARCH 20, 2016

Lege Artis Medicinae - 2016;26(03)

[SGLT-2-inihibitors are considered as a new class among oral antidiabetic drugs. The first derivatives of this class became available in the last couple of years in Hungary. According to the requirements from regulatory bodies, randomized, controlled clinical trials have been initiated in order to evaluate the cardiovascular safety of nearly all new antidiabetic drugs in patients with type 2 diabetes. Among SGLT-2-inhibitors, only one trial with empagliflozine has been completed so far. Based on the endpoints of the EMPA-REG OUTCOME trial a significant decrease in different cardiovascular events and total mortality was observed in type 2 diabetic patients with elevated cardiovascular risk. The exact pathomechanism of this beneficial effect has not been clearly understood. Currently, the position statements and scientific guidelines clearly describe the place of SGLT-2-inhibitor drugs in the treatment algorithm; the beneficial effect of empagliflozine on cardiovascular events should seriously be considered when making therapeutic decision. Together with the results of ongoing studies with SGLT-2-inhibitors (dapagliflozine: DECLARE, canagliflozine: CANVAS), these data will provide a more robust evidence about the cardiovascular safety of this new class of oral antidiabetic drugs. ]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Possibilites of modern, evidence based prevention of recurrent cystitis]

GANYECZ Máté, KÖVES Béla, TENKE Péter

[Recurrent cystitis is a very common disease in women; every second women experiences at least one episode of acute cystitis during their lifetime, and in 20% of the cases it develops to recurrent cystitis. The disease also has a significant negative impact on quality of life. In 60% percent of the cases mild-severe depression can be shown, which can be reduced by 30-40% with the properly chosen prophylaxis. Therefore the up-to-date knowledge of the evidence based recommendations on disease management is mandatory to all clinicans dealing with this patient group. In case of a recurrent urinary tract infection treatment of the actual episode is not enough. Rather, emphasis has to be placed on appropriate prevention strategy. Alway non-antimicrobial methods has to be preferred as first choice, antibiotic prophylaxis should be considered only when the non-antimicrobials have been unsuccessful. In this review the authors summarise the evidence based management options of recurrent urinary tract infections in detail, based on the guideline recommendations of the European Association of Urology. ]

Lege Artis Medicinae

[End-of-Life Decision Situations Physician-Assisted Death: Quebec, Canada ]

KŐMÜVES Sándor

Lege Artis Medicinae

[Expert comment on „Electronic cigarette use among students in higher education”]

HORVÁTH Ildikó

Lege Artis Medicinae

[The Son of Saul Face to Face with Darkness ]

LENGYEL Dávid

Lege Artis Medicinae

[Tuberculous meningoencephalitis in a toddler child]

REISZ Zita, GÁL Péter, TAJTI Zsanett, TERHES Gabriella, URBÁN Edit, KISS Ildikó, BARZÓ Pál, KIS Dávid, SENONER Zsuzsanna, SZABÓ Nóra, SZAPPANOS Norbert, TISZLAVICZ László

[INTRODUCTION - Central nervous system complications occur in 1% of patients with Mycobacterium tuberculosis infection, but the mortality is very high, about 50 percent. CASE REPORT - A 1-year-old child in tenebrous condition was admitted to the hospital with suspicion of meningitis. MRI detected disseminated encephalitis and dilated ventricles. Examination of the serum and cerebrospinal fluid didn’t bring any results. The microscopic examination of the brain biopsy raised the possibility of tuberculous meningoencephalitis, and the culture and PCR from the brain tissue revealed meningoencephalitis caused by Mycobacterium tuberculosis Beijing. DISCUSSION - Tuberculous meningitis is a very rare, but severe consequence of extrapulmonary tuberculosis. Due to the high mortality, early diagnosis and whenever suspected, the use of empiric antituberculotic therapy are the only chances of recovery.]

All articles in the issue

Related contents

LAM Extra for General Practicioners

[PYCNOGENOL IN THE CLINICAL PRACTICE]

KISS István, TAVASZY Mariann, FARSANG Csaba

[Polyphenols, which belong to the group of flavonoids, can be found in a number of plants, and are present in a high concentration in the French maritime pine bark. The authors summarise results of large-scale experimental and clinical studies on pycnogenol, the standardised extract of French maritime pine bark. Pycnogenol decreases production and effects of free radicals (antioxidant effect). It has antiinflammatory properties, and, by the stimulation of eNOSsynthesis, it increases the production of vasodilatory compounds (e.g. NO, prostacyclin) and decreases that of vascoconstrictor compounds (endothelin-1, thromboxane) materials. These changes lead to vasodilation, which results in increased tissue perfusion and decreased blood pressure. Pycnogenol also decreases platelet aggregation and LDL-cholesterol level and increases HDL-cholesterol level. Its antidiabetic effect has also been shown. Consequently, it may substantially decrease cardiovascular risk. In addition to these results, pycnogenol has been also found to have antibacterial and antiviral effects. It has been successfully used in children with attention deficit hyperactivity disorder, as well as in adults with dysmenorrhea, climacterial disturbances, glaucoma or asthma bronchiale.]

Lege Artis Medicinae

[Effect of beta blockers in hypertension, ischaemic heart disease, heart failure and metabolic syndrome]

BENCZÚR Béla

[Beta-blockers are among the most widely used drugs for the treatment of cardiovascular diseases. In the mid-90’s, these drugs were recommended as first-line therapies of hypertension. With the introduction of new drugs, the list of first-choice drugs has been extended. The results of recently published major hypertension trials, which compared conventional agents (beta blockers and/or diuretics) with newer agents (angiotensin converting enzyme inhibitors, Caantagonists, angiotensin receptor blockers), raised concerns regarding the role of beta blockers in cardiovascular primary prevention. Subsequently, a metaanalysis of 13 trials has shown that compared with other drug types, beta-blocker therapy is less beneficial in patients with hypertension who do not have heart disease. Nevertheless, in cardiovascular indications other than hypertension (acute myocardial infarction, heart failure and arrhythmias), betablockers retain their dominant position.]

Lege Artis Medicinae

[Treatment of cardiovascular risk of patients with hypertension: the role of fixed combination amlodipin-atorvastatin therapy in light of recent studies]

ALFÖLDI Sándor

[Risk factors for cardiovascular disease commonly coexist in patients with hypertension: high blood pressure is accompanied by alterations of lipid and glucose metabolism, obesity or smoking in the vast majority (70-80%) of patients. In the presence of multiple risk factors, the increment of relative cardiovascular risk caused by individual risk factors is not additive but multiplied. Since the ASCOT trial was published, statin therapy is recommended to every hypertensive patients with LDL cholesterol >2.5 mmol/L and at least intermediate cardiovascular risk (Euro SCORE>3%). Some studies show, however, that in daily clinical practice, blood pressure and lipid targets are achieved in a small percentage of patients with hypertension and dyslipidaemia. This is partly due to the fact that borderline alterations of serum cholesterol and their risk-increasing effects are often neglected during the planning of the therapy, and therapeutic adherence and persistence of patients are insufficient. According to new studies, both factors can be improved significantly if the antihypertensive and lipid-lowering treatments are initiated simultaneously, using a single pill with dual effect.]

Lege Artis Medicinae

[SELECTIVE α1-ADRENORECEPTOR ANTAGONISTS IN CARDIOVASCULAR MEDICINE]

RÓNASZÉKI Aladár

[A hypertonia korszerű kezelésében a szelektív α1-adrenoreceptor-antagonisták ma is jelentős szerepet játszanak. A hatékony vérnyomáscsökkentés mellett számos előnyös, járulékos hatásuk révén sok társbetegséget (diabetes mellitus, atherogen dyslipidaemia, obliteratív érbetegség, prostatahypertrophia, erectilis diszfunkció) is kedvezően befolyásolnak. A hypertoniához társuló szívelégtelenségben, illetve annak elkerülése érdekében monoterápiában nem alkalmazhatók. Az α1-adrenoreceptor-antagonisták kombinációja diuretikummal mindig javasolt.]

Lege Artis Medicinae

[RECOGNITION AND MANAGEMENT OF ACUTE HEART FAILURE]

KARLÓCAI Kristóf

[Acute heart failure may develop in previously healthy hearts. Nevertheless, structural abnormalities can facilitate its development and also, chronic heart failure can progress into acute stage. Considering the total cost of care in the patient's life, this is the most expensive heart disease. The clinical signs and physical abnormalities are usually of diagnostic power, however, instrumental investigations are necessary to recognize complications and to guide therapy. Patients should be monitored in well equipped coronary care units. Therapy consists of medications, coronary revascularization and use of mechanical assist devices.]